|Min SIP Amount||Not Supported|
|NAV||₹21.39 (22 Jun 2021)|
|Fund Started||04 Feb 2015|
|Fund Size||₹37 Cr|
|Gland Pharma Ltd.||Healthcare||Equity||6.2%|
|Cholamandalam Investment & Finance Co. Ltd.||Financial||Equity||5.9%|
|Elgi Equipments Ltd.||Engineering||Equity||5.8%|
|HDFC Bank Ltd.||Financial||Equity||5.6%|
|Reliance Industries Ltd.||Energy||Equity||5.6%|
|Larsen & Toubro Ltd.||Construction||Equity||5.3%|
|Tube Investments Of India Ltd.||Automobile||Equity||5.3%|
|ICICI Bank Ltd.||Financial||Equity||5.1%|
|Camlin Fine Sciences Ltd.||Chemicals||Equity||5.0%|
|MTAR Technologies Ltd.||Services||Equity||4.6%|
SBI Long Term Advantage Fund Series I Direct Growth is a Equity Mutual Fund Scheme launched by SBI Mutual Fund. This scheme was made available to investors on 04 Feb 2015. Rama Iyer Srinivasan, Nidhi Chawla is the Current Fund Manager of SBI Long Term Advantage Fund Series I Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹37 Cr and the Latest NAV as of 22 Jun 2021 is ₹21.39.
The SBI Long Term Advantage Fund Series I Direct Growth is rated Very High risk.
The scheme seeks to generate capital appreciation over a period of ten years by investing predominantly in equity and equity-related instruments of companies along with income tax benefit.